Moreover, it was reported that patients who eventually developed AD had considerably higher levels of 181-tau and/or p-S396-tau in their NDEs compared to their plasma, even 10 years prior to diagnosis, compared to those who did not develop AD (Fiandaca et al., 2015; Winston et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.